Fortress Biotech, Inc. (FBIO)
Nasdaq · Healthcare · Biotechnology
$2.09+2.96%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $69.7M
- P/E (trailing)
- 0.8
- 52-week range
- $2.00 – $4.53
- 52-week change
- −33.44%
- EPS (trailing)
- $2.76
Fiscal year to Dec 2025
- Revenue
- $63.3M (+9.69%)
- Net income
- $37.0M
- Operating margin
- −111.0%
- Diluted EPS
- −$0.07
From the company’s annual report on SEC EDGAR.
About Fortress Biotech, Inc.
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Headquarters: Bay Harbor Islands, United States · 78 employees · fortressbiotech.com